Bumper crop of new drugs fails to lift big pharma R & D returns

LONDON (Reuters) - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Health | Pharmaceuticals